.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Healthtrust
Fish and Richardson
Baxter
Daiichi Sankyo
AstraZeneca
Mallinckrodt
Cantor Fitzgerald
Argus Health

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Aerosol composition comprising formoterol
Abstract:The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 .mu.g to 5000 .mu.g per .mu.g of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.
Inventor(s): Haeberlin; Barbara (Muenchenstein, CH)
Assignee: Novartis, AG (Basel, CH)
Application Number:10/148,043
Patent Claims: 1. A method of treating chronic obstructive pulmonary disease consisting essentially of administering by inhalation to a subject in need of such treatment an effective amount of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate or said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of 400 .mu.g to 5,000 .mu.g per .mu.g of (A), wherein said pharmaceutically acceptable diluent or carrier has a median particle diameter of 40 to 100 .mu.m, and said formoterol is the only active ingredient.

2. A method according to claim 1, in which the formoterol (A) is in the form of formoterol fumarate dihydrate.

3. A method of treating chronic obstructive pulmonary disease which comprises administering by inhalation to a subject in need of such treatment an effective amount of a dry powder consisting, or consisting essentially, of (A) formoterol fumarate dihydrate and (B) a pharmaceutically acceptable diluent or carrier in an amount from 400 .mu.g to 5,000 .mu.g per .mu.g of (A), wherein said pharmaceutically acceptable diluent or carrier has a median particle diameter of 40 to 100 .mu.m.

4. A method according to claim 3, in which the diluent or carrier (B) is a saccharide, a sugar alcohol or a mixture thereof.

5. A method according to claim 4, in which the diluent or carrier (B) is lactose.

6. A method according to claim 3, in which the diluent or carrier (B) is present in an amount of 800 to 3000 .mu.g per .mu.g of (A).

7. A method according to claim 3, in which the mean particle diameter of (A) is up to 10 .mu.m.

8. A method according to claim 3, in which the dry powder is in a capsule, the capsule containing a unit dose of (A).

9. A method according to claim 8, in which the capsule contains 12 .mu.g of (A) and 19988-24988 .mu.g of diluent or carrier (B).

10. A method according to claim 3, in which the dry powder is in a reservoir of a multi-dose powder inhaler adapted to deliver a unit dose of (A) per actuation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
McKinsey
Colorcon
Merck
Federal Trade Commission
Dow
Farmers Insurance
Queensland Health
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot